Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ruxolitinib in Combination With High Dose Therapy and Autologous Stem Cell Transplantation for Myelofibrosis

NCT02469974 is registered in ClinicalTrials.gov with Marina Kremyanskaya as lead sponsor.

NCT NCT02469974
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02469974 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ruxolitinib in Combination With High Dose Therapy and Autologous Stem Cell Transplantation for Myelofibrosis
Lead sponsor
Marina Kremyanskaya
Phase
Not applicable
Overall status
Withdrawn
Start date
May 31, 2015
Completion date
August 31, 2016
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

mf, myelofibrosis